Evaluation of Pasireotide Pharmacokinetics Administered Subcutaneously via Reusable Pen Versus Syringe in Post-Bariatric Hypoglycaemia Patients

The primary objective of this study is to evaluate whether the medication **pasireotide** is absorbed and processed similarly when administered subcutaneously using either a reusable pen or a syringe in healthy subjects. This is clinically relevant as it may inform the optimal delivery method for **pasireotide**, potentially impacting its efficacy and safety profile in managing conditions such as post-bariatric hypoglycaemia.

The clinical trial focuses on individuals diagnosed with **post-bariatric hypoglycaemia**. The study population includes both male and female participants, with an age range categorized as adults. The general health status of the participants is not specified, and the total number of participants is not provided by the sponsor. The trial population was selected without targeting any vulnerable groups. Lifestyle considerations such as diet, physical activity, or habits are not detailed in the available data. Key inclusion or exclusion criteria are not specified, as the sponsor has not provided this information.

The clinical trial is designed to evaluate the pharmacokinetics of **pasireotide** when administered subcutaneously using either a reusable pen or a syringe in healthy subjects. This study is a Phase 3, randomized, double-blind, controlled trial. The trial is expected to commence on August 1, 2025, and conclude by October 30, 2025. Participants will be involved in the study for the duration of the trial, with specific visits scheduled to monitor their progress and gather necessary data.

The sequence of study visits includes an initial inclusion (screening) visit, where eligibility criteria are assessed to ensure participants meet the study requirements. Following successful screening, participants will be randomized to receive the study medication via one of the two administration methods. Throughout the trial, follow-up visits will be conducted to monitor the participants' health, assess the absorption and processing of the medication, and ensure adherence to the study protocol. The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments and data collection will occur.

Participant involvement is expected to last until the end of the trial, unless conditions arise that necessitate early termination. Such conditions may include adverse reactions to the medication, non-compliance with the study protocol, or withdrawal of consent by the participant. The trial aims to provide valuable insights into the administration of pasireotide, contributing to the understanding of its pharmacokinetics in healthy individuals.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. As such, no further details can be included in this description.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on August 1, 2025, with an estimated completion date of October 30, 2025. The efficacy assessment will be conducted using predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured protocol to ensure the collection and analysis of efficacy data is consistent and reliable. The study will adhere to rigorous standards typical of Phase 3 trials, focusing on evaluating the treatment's effectiveness in a larger population. The trial's design and execution will be aligned with regulatory requirements to ensure the validity and reliability of the efficacy outcomes.